The U.S. Securities and Exchange Commission says a former executive at Los Angeles-based Puma Biotechnology Inc. pocketed nearly $1.2 million in illicit profits by illegally trading on confidential information about an experimental breast cancer drug. Robert Gadimian, who was Puma’s senior director of regulatory affairs, was charged by the SEC Thursday with insider trading for allegedly […]